No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

byKathleen Lau

January 14, 2021

in StudyGraphics

RELATED REPORTS

AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited-stage small cell lung cancer

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

#VisualAbstract: Cadonilimab Plus Chemotherapy Improves Survival in Recurrent or Metastatic Cervical Cancer

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

RelatedReports

Dacomitinib may be effective in EGFR-associated lung cancer

Pharma

AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited-stage small cell lung cancer

December 30, 2024

StudyGraphics

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

December 26, 2024

StudyGraphics

#VisualAbstract: Cadonilimab Plus Chemotherapy Improves Survival in Recurrent or Metastatic Cervical Cancer

December 19, 2024

Natural language processing may automate data extraction from radiologic reports

Oncology

GPT-4 performing with superior scores on medical oncology examination questions

December 17, 2024

Prescription of antibiotics for acute respiratory infections increasing

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

Novel coronavirus identified from patients with pneumonia in Wuhan, China

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result